Bilal Abid, MD, Discusses Bispecifics Versus CAR-T in the Community Setting
By Melissa Badamo, Patrick Daly, Bilal Abid, MD - Last Updated: October 24, 2024Dr. Abid, of the University of Texas Health Science Center at Houston, joins Blood Cancers Today at the Twelfth Annual Meeting of the Society of Hematologic Oncology to discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematologic malignancies in the community setting.
Advertisement
Post Tags:SOHO 2024
Advertisement
Related Posts
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.